Hostname: page-component-6b989bf9dc-94dtm Total loading time: 0 Render date: 2024-04-15T00:48:55.229Z Has data issue: false hasContentIssue false
  • English
  • Français

Are antidepressants effective in quality of life improvement among children and adolescents? A systematic review

Published online by Cambridge University Press:  13 September 2013

Dejan Stevanovic ,
Ivana Tadic  and
Rajna Knez
Dejan Stevanovic*
Affiliation:
Department of Psychiatry, General Hospital Sombor, Sombor, Serbia
Ivana Tadic
Affiliation:
Department of Social Pharmacy and Pharmacy Legislation, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
Rajna Knez
Affiliation:
Department of Psychiatry, Rijeka University Hospital Centre, Rijeka, Croatia
*
*Address for correspondence: Dejan Stevanovic, MD, Department of Psychiatry, General Hospital Sombor, Apatinski put 38, 25000 Sombor, Serbia. Email dejanstevanovic@eunet.rs
Get access Rights & Permissions [Opens in a new window]

Abstract

There is some evidence indicating that psychotropic medications might lead to health-related quality of life (QOL) improvements among children and adolescents with psychiatric disorders. The aim of this systematic review is to assess evidence regarding whether antidepressant treatment improves QOL among children and adolescents with depressive or anxiety disorders. A comprehensive search resulted in 5 clinical trials to be included in this review: 4 trials with major depressive disorder (MDD) and 1 trial with social anxiety disorder (SAD). In one MDD trial, fluoxetine combined with cognitive behavior therapy (CBT) significantly improved QOL compared to fluoxetine or CBT alone (effect sizes were 0.53 and 0.69, respectively). In 2 combined trials, sertraline alone significantly improved QOL among adolescents with MDD (effect size was 0.29), but not among children with MDD. Essentially, it was observed that antidepressants in these trials had minor positive effects on QOL improvement, which were lower than their potential to improve depressive symptoms. Although fluoxetine with CBT or sertraline monotherapy were shown to have some potential to improve QOL, this systematic review found inconclusive evidence that antidepressant treatments improve QOL among children and adolescents with depressive or anxiety disorders. More research is required, considering that QOL is currently under-evaluated in clinical trials with antidepressants among children and adolescents and available trials have limited methodological quality when reporting QOL data.

Keywords

Anxiety disordersclinical trialdepressionefficacyquality of life
Type
Review Articles
Information
CNS Spectrums , Volume 19 , Issue 2 , April 2014 , pp. 134 - 141
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Hennessy, CH, Moriarty, DG, Zack, MM, etal. Measuring health-related quality of life for public health surveillance. Public Health Rep. 1994; 109(5): 665–672.Google Scholar
2. Acquadro, C, Berzon, R, Dubois, D, etal. Incorporating the patient's perspective into drug development and communication: an Ad Hoc Task Force report on the Patient-Reported Outcomes (PRO) Harmonization Group Meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003; 5: 522–531.Google Scholar
3. Chassany, O, Sagnier, P, Marquis, P, etal. Patient-reported outcomes: the example of health-related quality of life—a European guideline document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Information Journal. 2002; 36(1): 209–238.Google Scholar
4. Fayers, PM, Machin, D. Quality of Life: The Assessment, Analysis and Interpretation of Patient-Reported Outcomes, 2nd ed. Chichester, UK: John Wiley & Sons; 2007.Google Scholar
5. Dey, M, Landolt, MA, Mohler-Kuo, M. Health-related quality of life among children with mental disorders: a systematic review. Qual Life Res. 2012; 21(10): 1797–1814.Google Scholar
6. Sawyer, MG, Whaites, L, Rey, JM, etal. Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry. 2002; 41(5): 530–537.Google Scholar
7. Bastiaansen, D, Koot, HM, Ferdinand, RF, Verhulst, FC. Quality of life in children with psychiatric disorders: self-, parent, and clinician report. J Am Acad Child Adolesc Psychiatry. 2004; 43(2): 221–230.Google Scholar
8. Karande, S, Bhosrekar, K, Kulkarni, M, Thakker, A. Health-related quality of life of children with newly diagnosed specific learning disability. J Trop Pediatr. 2009; 55(3): 160–169.Google Scholar
9. Kuhlthau, K, Orlich, F, Hall, T, etal. Health-related quality of life in children with autism spectrum disorders: results from the Autism Treatment Network. J Autism Dev Disord. 2010; 40(6): 721–729.CrossRefGoogle ScholarPubMed
10. Matza, LS, Rentz, AM, Secnik, K, etal. The link between health related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2004; 25(3): 166–174.CrossRefGoogle ScholarPubMed
11. Rotsika, V, Coccossis, M, Vlassopoulos, M, etal. Does the subjective quality of life of children with specific learning disabilities (SpLD) agree with their parents’ proxy reports? Qual Life Res. 2011; 20(8): 1271–1278.Google Scholar
12. Escobar, R, Soutullo, CA, Hervas, A, etal. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics. 2005; 116(3): e364–e369.Google Scholar
13. Bastiaansen, D, Koot, HM, Ferdinand, RF. Psychopathology in children: improvement of quality of life without psychiatric symptom reduction? Eur Child Adolesc Psychiatry. 2005; 14(7): 364–370.Google Scholar
14. Katschnig, H. Quality of life in mental disorders: challenges for research and clinical practice. World Psychiatry. 2006; 5(3): 139–145.Google Scholar
15. Committee for Medicinal Products for Human Use (CMPH). Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. London: European Medicines Agency. http://www.emea.europa.eu/pdfs/human/ewp/13939104en.pdf (Accessed July 25, 2005).Google Scholar
16. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research. Guidance for industry: patient-reported outcome measures—use in medical product development to support labeling claims. Federal Register. 2009; 74: 65132–65133.Google Scholar
17. Revicki, D, Erickson, PA, Sloan, JA, etal. Interpreting and reporting results based on patient-reported outcomes. Value Health. 2007; 10: S116–S124.CrossRefGoogle ScholarPubMed
18. Brundage, M, Bass, B, Davidson, J, etal. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res. 2011; 20(5): 653–664.Google Scholar
19. IsHak, WW, Greenberg, JM, Balayan, K, etal. Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry. 2011; 19(5): 229–239.Google Scholar
20. Olatunji, BO, Cisler, JM, Tolin, DF. Quality of life in the anxiety disorders: a meta-analytic review. Clin Psychol Rev. 2007; 27(5): 572–581.Google Scholar
21. Danckaerts, M, Sonuga-Barke, JS, Banaschewski, T, etal. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010; 19(2): 83–105.Google Scholar
22. Vitiello, B, Rohde, P, Silva, S, etal. Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006; 45(12): 1419–1426.Google Scholar
23. Donnelly, CL, Wagner, KD, Rynn, M, etal. Sertraline in children and adolescents with major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2006; 45(10): 1162–1170.Google Scholar
24. Murray, ML, de Vries, CS, Wong, IC. A drug utilization study of antidepressants in children and adolescents using the General Practice Research Database. Arch Dis Child. 2004; 89(12): 1098–1102.Google Scholar
25. Zito, JM, Tobi, H, de Jong-van den Berg, LT, etal. Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf. 2006; 15(11): 793–798.Google Scholar
26. Dean, AJ, Hendy, A, McGuire, T. Antidepressants in children and adolescents—changes in utilization after safety warnings. Pharmacoepidemiol Drug Saf. 2007; 16(9): 1048–1053.Google Scholar
27. Wijlaars, LPMM, Nazareth, I, Petersen, I. Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS ONE. 2012; 7(3): e33181.Google Scholar
28. Clarke, SA, Eiser, C. The measurement of health related quality of life (QOL) in pediatric clinical trials: a systematic review. Health Qual Life Outcomes. 2004; 2: 66.Google Scholar
29. Solans, M, Pane, S, Estrada, MD, etal. Health-related quality of life measurement in children and adolescents: a systematic review of generic and disease-specific instruments. Value Health. 2008; 11(4): 742–764.Google Scholar
30. Hazell, P, O'Connell, D, Heathcote, D, Henry, D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev. 2002; (2): CD002317.Google ScholarPubMed
31. Hetrick, SE, McKenzie, JE, Cox, GR, Simmons, MB, Merry, SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2012; 11: CD004851.Google ScholarPubMed
32. Henry, A, Kisicki, MD, Varley, C. Efficacy and safety of antidepressant drug treatment in children and adolescents. Mol Psychiatry. 2012; 17(12): 1186–1193.Google Scholar
33. Efficace, F, Bottomley, A, Osoba, D, etal. Beyond the development of health-related quality of life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials—does HRQOL evaluation in prostate cancer research inform clinical decision-making? J Clin Oncol. 2003; 21(18): 3502–3511.Google Scholar
34. Brundage, M, Bass, B, Davidson, J, etal. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res. 2011; 20(5): 653–664.Google Scholar
35. Cohen, J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.Google Scholar
36. Byford, S, Barrett, B, Roberts, C, etal. Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive behavioural therapy in adolescents with major depression. Br J Psychiatry. 2007; 191: 521–527.Google Scholar
37. Goodyer, IM, Dubicka, B, Wilkinson, P, etal. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors: the ADAPT trial. Health Technol Assess. 2008; 12(14): iii–iv;, ix–60.Google Scholar
38. Goodyer, I, Dubicka, B, Wilkinson, P, etal. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behavior therapy in adolescents with major depression: randomized controlled trial. BMJ. 2007; 335(7611): 142.CrossRefGoogle Scholar
39. Wagner, KD, Ambrosini, P, Rynn, M, etal. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA. 2003; 290(8): 1033–1041.Google Scholar
40. Rynn, M, Wagner, KD, Donnelly, C, etal. Long-term sertraline treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2006; 16(1–2): 103–116.Google Scholar
41. Domino, ME, Foster, EM, Vitiello, B, etal. Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. J Am Acad Child Adolesc Psychiatry. 2009; 48(7): 711–720.Google Scholar
42. Isolan, L, Pheula, G, Salum, GA Jr, etal. An open-label trial of escitalopram in children and adolescents with social anxiety disorder. J Child Adolesc Psychopharmacol. 2007; 17(6): 751–760.Google Scholar
43. EuroQol—a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16(3):199–208.Google Scholar
44. Endicott, J, Nee, J, Yang, R, Wohlberg, C. Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q): reliability and validity. J Am Acad Child Adolesc Psychiatry. 2006; 45(4): 401–407.CrossRefGoogle ScholarPubMed
45. Patrick, DL, Edwars, TC, Topolski, TD. Adolescent quality of life, part II: initial validation of a new instrument. J Adolesc. 2002; 25(3): 287–300.CrossRefGoogle ScholarPubMed
46. Poznanski, E, Mokros, H. Children's Depression Rating Scale—Revised (CDRS-R). Los Angeles, CA: WPS; 1995.Google Scholar
47. Birmaher, B, Brent, DA, Chiappetta, L, etal. Psychometric properties of the Screen for Child and Anxiety Related Emotional Disorders (SCARED): a replication study. J Am Acad Child Adolesc Psychiatry. 1999; 38(10): 1230–1236.Google Scholar
48. Papakostas, GI, Petersen, T, Mahal, Y, etal. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry. 2004; 26: 13–17.Google Scholar
49. Stevanovic, D. Impact of emotional and behavioral symptoms on quality of life in children and adolescents. Qual Life Res. 2013; 22(2): 333–337.CrossRefGoogle ScholarPubMed
50. Reed, C, Monz, BU, Perahia, DG, etal. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord. 2009; 113: 296–302.Google Scholar
51. Angermeyer, MC, Holzinger, A, Matschinger, H, Stenger-Wenzke, K. Depression and quality of life: results of a follow-up study. Int J Soc Psychiatry. 2002; 48(3): 189–199.Google Scholar
52. Rapaport, MH, Clary, C, Fayyad, R, Endicott, J. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry. 2005; 162(6): 1171–1178.CrossRefGoogle ScholarPubMed
53. Wille, N, Badia, X, Bonsel, G, etal. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010; 19(6): 875–886.Google Scholar
54. Upton, P, Lawford, J, Eiser, C. Parent–child agreement across child health-related quality of life instruments: a review of the literature. Qual Life Res. 2008; 17(6): 895–913.CrossRefGoogle ScholarPubMed
55. Johnston, BC, Thorlund, K, Schünemann, HJ. Improving the interpretation of quality of life evidence in meta-analyses: the application of minimal important difference units. Health Qual Life Outcomes. 2010; 8: 116.Google Scholar
56. Calvert, M, Blazeby, J, Altman, DG, etal. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013; 309(8): 814–822.Google Scholar
57. Coghill, D. Pragmatic measures in paediatric psychopharmacology—are we getting it right? Eur Neuropsychopharmacol. 2011; 21(8): 571–583.Google Scholar
Supplementary material: File

Stevanovic Supplementary Material

Appendix

Download Stevanovic Supplementary Material(File)
File 46.1 KB